- Conditions
- Severe Eosinophilic Asthma, Nasal Polyps
- Interventions
- FASENRA(benralizumab)
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Centennial, Colorado • Denver, Colorado • Glendale, New York + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 4,416
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II
- Interventions
- Not listed
- Lead sponsor
- Novartis
- Industry
- Eligibility
- Up to 14 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Chronic Rhinosinusitis
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 966 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- assessment of therapy complications
- Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Up to 120 Years
- Enrollment
- 3,571 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 451
- States / cities
- Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
- Conditions
- Chronic Pain
- Interventions
- Cannabidiol, Placebo
- Drug
- Lead sponsor
- Staci Gruber, Ph.D.
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Smoking Cessation, Cancer, Treatment-Related
- Interventions
- Varenicline, Bupropion, Long-acting nicotine replacement therapy, Low-intensity counseling, High-intensity counseling, No nicotine replacement therapy, Nicotine Replacement Products
- Drug · Behavioral · Other
- Lead sponsor
- Joseph Valentino, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Bowling Green, Kentucky • Lexington, Kentucky • Owensboro, Kentucky
- Conditions
- End Stage Renal Failure on Dialysis
- Interventions
- Amino acid supplementation NephrAmine®
- Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Dural Sealing
- Interventions
- DuraSeal Exact Spine Sealant System, Control
- Device · Other
- Lead sponsor
- Integra LifeSciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 924 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more
- Conditions
- Intracranial Neoplasm
- Interventions
- Magnetic Resonance Imaging, Oxygen Therapy
- Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Depression
- Interventions
- PRogram In Support of Moms (PRISM), MCPAP for Moms
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation (TUNA) Therapy, Finasteride and Alfuzosin
- Device · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Chicago, Illinois • Rochester, Minnesota + 4 more
- Conditions
- Effects of Chemotherapy
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 11 Years to 50 Years · Female only
- Enrollment
- 391 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2020
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Radnor, Pennsylvania
- Conditions
- Granulomatous, Mastitis
- Interventions
- Not listed
- Lead sponsor
- Granulomatous Mastitis Working Group
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
- Interventions
- Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Dinutuximab, Echocardiography Test, FDG-Positron Emission Tomography, Iberdomide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nuclear Radiology Imaging Procedure, Sargramostim, Topotecan
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Neoplasm Metastasis
- Interventions
- Cryoablation
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Newnan, Georgia • Rochester, Minnesota + 4 more
- Conditions
- Pain, Postoperative, Total Knee Arthroplasty
- Interventions
- Duloxetine, Placebos
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma
- Interventions
- Biospecimen Collection, Dietary Intervention, Medical Chart Review, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Surgical Wound
- Interventions
- Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)
- Device
- Lead sponsor
- Cardiva Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Ridgewood, New Jersey • Austin, Texas
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Proactive Panel Management Clinics for HFrEF
- Other
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Colon Cancer
- Interventions
- FOLFOX and bevacizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
- Interventions
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Tuvusertib, X-Ray Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 14
- States / cities
- Augusta, Georgia • Chicago, Illinois • Iowa City, Iowa + 8 more
- Conditions
- SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
- Interventions
- AVTX-801, Placebo
- Drug
- Lead sponsor
- Eva Morava-Kozicz
- Other
- Eligibility
- 1 Month and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hemophilia A
- Interventions
- No intervention
- Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Sacramento, California • New Orleans, Louisiana • Minneapolis, Minnesota
- Conditions
- Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
- Interventions
- Impella 5.5 SmartAssist
- Device
- Lead sponsor
- Abiomed Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 17
- States / cities
- Tampa, Florida • Indianapolis, Indiana • Minneapolis, Minnesota + 13 more